Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in C R Bard Inc (NYSE:BCR) by 26.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,343 shares of the medical instruments supplier’s stock after buying an additional 1,128 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in C R Bard were worth $1,328,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Cribstone Capital Management LLC purchased a new stake in C R Bard during the first quarter worth approximately $130,000. Contravisory Investment Management Inc. boosted its stake in C R Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 426 shares during the period. Whittier Trust Co. boosted its stake in C R Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares during the period. SRS Capital Advisors Inc. purchased a new stake in C R Bard during the fourth quarter worth approximately $133,000. Finally, Intrust Bank NA purchased a new stake in C R Bard during the first quarter worth approximately $212,000. Institutional investors and hedge funds own 86.89% of the company’s stock.
Shares of C R Bard Inc (NYSE:BCR) traded down 0.07% during trading on Friday, hitting $308.38. The stock had a trading volume of 134,834 shares. The firm’s 50-day moving average is $289.00 and its 200 day moving average is $246.57. C R Bard Inc has a 52-week low of $203.63 and a 52-week high of $309.16. The firm has a market cap of $22.33 billion, a price-to-earnings ratio of 39.25 and a beta of 0.63.
C R Bard (NYSE:BCR) last posted its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. During the same quarter last year, the firm earned $2.34 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts expect that C R Bard Inc will post $11.78 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, May 12th. Investors of record on Monday, May 1st were issued a $0.26 dividend. The ex-dividend date was Thursday, April 27th. This represents a $1.04 annualized dividend and a dividend yield of 0.34%. C R Bard’s dividend payout ratio is presently 14.77%.
A number of equities analysts recently issued reports on BCR shares. Zacks Investment Research lowered C R Bard from a “buy” rating to a “hold” rating in a report on Friday, May 12th. Raymond James Financial, Inc. reissued a “market perform” rating and set a $265.00 price target on shares of C R Bard in a report on Tuesday, April 25th. JMP Securities raised their price target on C R Bard from $240.00 to $255.00 in a report on Friday, January 27th. Cowen and Company lifted their price objective on C R Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a report on Monday, April 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a report on Friday, January 27th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $264.92.
In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the sale, the vice president now owns 10,139 shares of the company’s stock, valued at $3,082,256. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.97% of the stock is currently owned by company insiders.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with our FREE daily email newsletter.